Elraglusib Plus Chemotherapy Shows Survival Gain In Pancreatic Cancer Trial

Investigators reported that adding elraglusib to standard chemotherapy was associated with longer overall survival than chemotherapy alone in metastatic pancreatic cancer. The comparison came from a randomized study evaluating whether the experimental agent could extend survival in this advanced disease setting. Researchers noted that the reported survival benefit could be applicable to a broad population of patients with pancreatic cancer. The trial readout focused on survival outcomes and the tolerability profile observed with the combination.

The report states that 233 patients with previously untreated metastatic pancreatic ductal adenocarcinoma were enrolled across 60 sites in six countries in North America and Europe. In the phase 2 randomized trial, participants were assigned to gemcitabine/nab-paclitaxel alone or the same regimen with elraglusib. Investigators described the study as an international test of whether adding the agent could improve outcomes over standard treatment. The comparison centered on adding elraglusib to established chemotherapy rather than replacing standard therapy.

The authors reported a median overall survival of 10.1 months with elraglusib plus chemotherapy and 7.2 months with chemotherapy alone. They also reported one-year survival proportions of 44% in the combination group and 22% in the chemotherapy group. At two years, about 13% of patients receiving elraglusib were alive, while no patients in the chemotherapy group remained alive. Across these reported summary endpoints (median overall survival and landmark 1- and 2-year survival proportions), outcomes were higher in the elraglusib-plus-chemotherapy group than with chemotherapy alone.

Researchers noted that adverse events were generally in line with chemotherapy effects, though they occurred somewhat more often when elraglusib was added. The most frequent events included low white blood cell counts, fatigue, and temporary vision changes described as reversible. Investigators characterized the overall safety profile as manageable despite the added toxicities seen with the combination.

Key takeaways:

• A randomized phase 2 study enrolled 233 patients across 60 sites in six countries and compared chemotherapy with or without elraglusib.
• Elraglusib plus chemotherapy was associated with longer overall survival and higher one-year and two-year survival proportions.
• Adverse events were reported as generally chemotherapy-like, somewhat more frequent with elraglusib, and manageable overall.